|
|
Volumn 26, Issue 2, 2008, Pages 151-154
|
|
Priced out of the UK market
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BEVACIZUMAB;
BORTEZOMIB;
CETUXIMAB;
DEXAMETHASONE;
DONEPEZIL;
ERLOTINIB;
FLUDARABINE PHOSPHATE;
GALANTAMINE;
GEMCITABINE;
IMATINIB;
NATALIZUMAB;
PEMETREXED;
RANIBIZUMAB;
RITUXIMAB;
RIVASTIGMINE;
ALZHEIMER DISEASE;
BIOTECHNOLOGICAL PROCEDURES;
BREAST CANCER;
CHRONIC MYELOID LEUKEMIA;
COLORECTAL CANCER;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG INDUSTRY;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LIFE EXPECTANCY;
LUNG CANCER;
MULTIPLE SCLEROSIS;
PRIORITY JOURNAL;
PSORIATIC ARTHRITIS;
QUALITY ADJUSTED LIFE YEAR;
RETINA MACULA AGE RELATED DEGENERATION;
RHEUMATOID ARTHRITIS;
SHORT SURVEY;
COST-BENEFIT ANALYSIS;
DRUG INDUSTRY;
GOVERNMENT REGULATION;
GREAT BRITAIN;
HEALTH CARE COSTS;
INSURANCE, HEALTH, REIMBURSEMENT;
MARKETING;
PHARMACEUTICAL PREPARATIONS;
|
|
EID: 38949120955
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0208-151 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (1)
|
